Answers are grounded in this paper and cite their sources.
The selective endothelin antagonist cyclo(D-Glu-L-Ala-D-allo-Ile-L-Leu-D-Trp, BE18257B) has been synthesized via solid-phase methods and its solution conformation determined by NMR spectroscopy and simulated annealing calculations based on NOE constraints. Additional information used in the structure determination included coupling constants and chemical-shift measurements as a function of temperature. The chemical shifts of two of the NH protons (D-Glu and D-Ile) exhibit low sensitivity to changes in temperature, indicating their involvement in hydrogen-bonded interactions. The main features of interest in the solution conformation include the presence of both a type-II beta-turn and an inverse gamma-turn, with central hydrogen bonds between HN of D-Glu1 and the C = O of D-allo-Ile3 and between HN of D-allo-Ile3 and the C = O of D-Glu1. The correlation of this solution conformation to the peptide's biological activity is discussed. The data are also compared with recently derived structures for BQ123, cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp), another highly potent endothelin antagonist. The backbone conformations of the two cyclic peptides are found to be similar. Comparisons with literature structure-activity data suggest that these peptides may mimic structural features of the C-terminal tail of the endothelins.
No takes yet. Share an insight, caveat, or question.
Coles et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: